OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On March28, 2017, Orexigen Therapeutics, Inc.
(Orexigen or the
Company) issued a press release
announcing its financial results for the three months and year
ended December31, 2016. A copy of this press release is attached
hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to
the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, except as expressly set forth by specific
reference in such filing to this Current Report on Form 8-K.
| Item9.01 | Financial Statements and Exhibits |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated March28, 2017 |
About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Recent Trading Information
OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) closed its last trading session up +0.11 at 4.24 with 231,581 shares trading hands.
